Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AZN

3 Pharma Stocks to Buy in 2023 and Hold for Decades

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

StockNews.com

2 Pharma Stocks to Buy Now for Big Gains

The pharma industry is well-placed to benefit from the rise of chronic diseases and an aging population. Moreover, given the stable demand for medicines, the industry is relatively unaffected by macroeconomic uncertainty. Therefore, it could be wise for investors to buy fundamentally strong pharma stocks AstraZeneca (AZN) and Novartis (NVS).…

StockNews.com

4 Pharma Stocks You Shouldn’t Think Twice About Buying in 2023

Pharma sector usually performs relatively well amid market turmoil due to the inelastic demand for its offerings. Moreover, increased technological advancements should boost the industry’s growth. Hence, pharma stocks Eli Lilly (LLY), AstraZeneca (AZN), Zoetis (ZTS), and Teva Pharmaceutical (TEVA) might be worth buying in 2023. Read more.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Which Stocks Show Thick Skin As Bears Sink Fangs Into New Year?

As last year's bear market spills over into 2023, breakout index stocks like CAT, BOX, AZN and ELF stock show resilience.

Investors Business Daily

IBD 50 Stocks To Watch: Pharmaceutical Leader AstraZeneca Retakes Latest Buy Point

Among the top stocks to watch, pharmaceutical leader AstraZeneca is retaking its latest buy point despite Tuesday's stock market weakness.

Investors Business Daily

4 Pharmaceutical Stocks You Can Always Rely On

The pharmaceutical industry is well-positioned to witness substantial growth, driven by the prevalence of chronic diseases, the aging population, and increased healthcare spending. Given the industry’s promising growth prospects, we think it could be wise to invest in fundamentally sound pharmaceutical stocks Johnson & Johnson (JNJ), Merck & Co (MRK),…

StockNews.com

5 Amazing Stocks You Won’t Ever Regret Buying

Easing inflation and the Fed’s indication of slowing the pace of interest rate hikes are raising investors’ sentiments. Moreover, the November job report came in better than expected. While uncertainties remain, we think quality stocks Pfizer (PFE), AstraZeneca PLC (AZN), Carrier Global (CARR), J. Jill (JILL), and Lifeway Foods (LWAY)…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth

AstraZeneca leaned on cancer drugs in the third-quarter, leading to double-digit sales growth, a strong beat and a jump for AZN stock.

Investors Business Daily

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

StockNews.com

Dow Jones Futures Fall As Market Retreat Gains Steam; Elon Musk Makes This FSD Move

Futures fell sharply as the market rally pulls back. Elon Musk will hike Tesla FSD prices. Warren Buffett stock Occidental Petroleum surged Friday.

Investors Business Daily

IBD Stock Of The Day AstraZeneca Stalls As Gilead Looks To Take Its Breast Cancer Market

AstraZeneca is the IBD Stock Of The Day amid growing enthusiasm for its cancer drug, Enhertu. But AZN stock hit resistance Monday.

Investors Business Daily

AstraZeneca Expects Flat 2022 Covid Sales — Which Is Better Than Expected

AstraZeneca raised its full-year sales guidance on strength from its Covid drugs, leading AZN stock to inch higher early Friday.

Investors Business Daily

AstraZeneca Eyes A Trio Of Drug Approvals And Maybe A Breakout

AstraZeneca announced looming approval for two drugs in Europe and an FDA review for a third med, leading AZN stock to inch higher Monday.

Investors Business Daily

This Is What Whales Are Betting On AstraZeneca

Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Fall, Crude Dives After Market Rally Runs Into China Wall

Stocks fell from resistance Monday on China news and looming inflation data. Tesla, Twitter and Alibaba were big losers.

Investors Business Daily

Stocks To Watch: Baidu, UnitedHealth Lead 5 Near Buy Points

Stocks to watch this coming week include a diverse group in or near buy zones, including Baidu and UnitedHealth.

Investors Business Daily

Dow Jones Futures Fall: Don't Feed The Bear Market; BYD Leaves Tesla In The Dust

Don't feed the bear market, prepare for the next bull run. Tesla deliveries fell sharply in Q2 with BYD on tap.

Benzinga

Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine

Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020. The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AstraZeneca Says Imfinzi/Chemo Combo Shows Promising Action In Late-Stage Lung Cancer Study

AstraZeneca Plc (NASDAQ:AZN) announced high-level results from a planned interim analysis of the AEGEAN Phase 3 trial of Imfinzi (durvalumab) combined with neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The data showed that Imfinzi plus neoadjuvant chemo before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete…

Investors Business Daily

Dow Jones Up As Powell Issues This Inflation Warning; Tesla Stock Falls Amid This Move; Apple Pops

The Dow Jones rose despite Fed Chair Jerome Powell issuing an inflation warning. Tesla stock fell amid closure news. Apple stock rose.

Benzinga

AstraZeneca Whale Trades For June 29

Investors Business Daily

Dow Jones Dips; Donald Trump SPAC Dives On This Move; Apple Stock Whipsaws Amid Wall Street Call

The Dow Jones fell. The Donald Trump SPAC took a dive amid legal woes. Apple stock treaded water after an analyst call.

Benzinga

What Are Whales Doing With AstraZeneca

Benzinga

AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

AstraZeneca Plc (NASDAQ:AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess copper is compromised. The data showed that ALXN1840 met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of…

Benzinga

Short Volatility Alert: AstraZeneca PLC

On Tuesday, shares of AstraZeneca PLC (NASDAQ: AZN) experienced volatile short activity. After the activity, the stock price went up 2.85% to $62.83. The overall sentiment for AZN has been Bullish.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.